HOME >> BIOLOGY >> NEWS
Screening programs find health problems among former Hanford workers

A press conference to outline the results of medical screenings of former Hanford workers will be held at 11 a.m. PST on Tuesday, Nov. 2, in the Columbia Room of the Richland Red Lion (formerly the DoubleTree).

The conference is sponsored by the University of Washington, The Coalition to Protect Workers' Rights, and the Department of Energy.

The conference will include representatives of those groups, plus former workers who will be available for interviews. Media unable to attend the conference can obtain information about the results, after the briefing, by calling the number above.

The two projects involved have screened about 600 workers so far, with plans to screen an additional 20,000 for health problems related to their work at the Hanford nuclear site in southeastern Washington state. These evaluations are the most extensive of former Hanford workers to date.

Undiagnosed lung disease and hearing loss are the most common ailments noted thus far.

The conference comes at the beginning of the third annual "Health of the Hanford Site" conference sponsored by the University of Washington. The data on former workers will be presented in full along with other topics related to human and ecological health at Hanford. The conference gives scientists, contractors, workers, residents, tribal representatives and others an opportunity to exchange information and discuss past, present and future research regarding the site.

Members of the media are welcome to cover some or all of the conference, also held at the Red Lion. For more information, call the number above or visit the conference Web site at http://depts.washington.edu/cresp2/hos. Besides worker health, other topics at the conference will include contaminated high-level waste tanks, beryllium exposure and evaluation of human and ecological health risks.

Among the scheduled topics:

    - The two new studies that quantify the number of health problems that have affected
    '"/>


Contact: Walter Neary
wneary@u.washington.edu
206-543-3620
University of Washington
26-Oct-1999


Page: 1 2

Related biology news :

1. Society for Biomolecular Screening to hold ninth annual conference
2. Screening technique streamlines search for anticancer drugs
3. Screening certain infants can be lifesaving, Wake Forest study shows
4. Screening embryos for problem chromosomes
5. American Red Cross Launches New Genetic Screening Technology To Directly Detect Viruses
6. H Pylori Screening To Reduce The Risk Of Gastric Cancer
7. Vibrating Cells Could Be The Ultimate In Noninvasive Screening
8. Screening In Women Army Recruits Shows High Chlamydia Infection Rates
9. Researchers Develop Fast Screening Method For Water Testing
10. Genetic Screening May Be Tool For Selecting Cancer Treatment, Research Suggests
11. Cancer Test May Offer High-Risk Groups Quick, Affordable Screening For Tumors

Post Your Comments:
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: